Ceapro Reports Second Quarter 2013 Financial Results
29 8월 2013 - 10:00PM
Marketwired Canada
Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the Company") today announced its
financial results for the three-month and six-month periods ended June 30, 2013.
Second quarter 2013 corporate highlights
-- Announcement of a Distribution Agreement signed with German- based
multinational, Symrise AG
-- Additional funding of up to $97,000 for a key research project as part
of a collaboration with a Canadian agriculture producer group
-- Initiation of new state of the art manufacturing facility construction
in Edmonton
Subsequent to quarter-end
-- Initiation of a research program to asses the suitability of dry
formulations of Beta Glucan and Avenanthramides for the large
nutraceuticals/functional food markets
-- $1,600,000 loan secured from Alberta Financial Corporation Services
(AFSC) for the acquisition of equipment in the new plant
-- Conclusion of non-repayable grant of up to $674,000 with Canadian
Government Growing Forward 2 Program for the new manufacturing plant
project
FINANCIAL RESULTS FOR THE SECOND QUARTER AND THE FIRST SIX MONTHS ENDED JUNE 30,
2013
Revenues were $1,012,000 for the three-month period ended June 30, 2013, as
compared to $1,490,000 for the same period in 2012. This decrease of revenues in
the second quarter of 2013 is mostly due to timing of customers' orders. For the
first six months, revenues were up to $3,025,000 in 2013 compared to $2,680,000
for the same period in 2012, representing an increase of 12.9%.
Gross Margins were $579,000 and $1,629,000 for the three-month period and
six-month period ended June 30, 2013 as compared to $673,000 and $1,342,000 for
the same periods in 2012. This significant six-month 21% improvement mostly
reflects increased sales of one higher margin product.
Research and Development Investments were $227,000 and $364,000 for the
three-month period and six-month period ended June 30, 2013 as compared to
$267,000 and $430,000 for the same periods in 2012. These decreased numbers in
2013 represent a favourable result from grant revenues recognition received from
government funding programs. We remain strongly committed to expand our pipeline
through the development of new products as well as the development of second
generation of products from our value drivers, Avenanthramides and Beta Glucan.
General and Administration Expenses were $437,000 and $873,000 for the
three-month period and six-month period ended June 30, 2013 compared to $490,000
and $881,000 for the same periods in 2012. These lower G&A expenses in Q2 2013
are due to lower consulting costs than the ones incurred in 2012 for feasibility
studies for the new plant. They are also due to the non-renewal in 2013 of a
contract for an investor relations firm and to lower legal expenses registered
in 2013 compared to 2012.
Sales and Marketing Expenses were $47,000 and $69,000 for the three-month and
six-month periods ended June 30, 2013 compared to $55,000 and $126,000 for the
same periods in 2012. These decreased expenses in 2013 are due to the
non-renewal of marketing feasibility studies conducted in 2012 partially offset
by Ceapro's participation at a major conference in April 2013.
Net Income/Loss. For the three-month period ended June 30, 2013, net loss was
$252,000 versus a net loss of $161,000 for the same period in 2012. This net
loss includes a relocation rent expense of $81,000 for the new facility. It also
includes $122,000 in new patents costs mostly issued in European Countries for
Beta Glucan. The relocation expenses are reported under "other operating income
(loss)" in the Profit and Loss statement. For the first six-months of 2012, net
profit amounted to $156,000 compared to a net loss of $164,000 for the same
period in 2012. Without the extraordinary expenses incurred in Q2 2013 for the
new rent and patents, net income for the first six months of 2013 would amount
to $359,000 compared to a loss of $164,000 for the same period in 2012.
"We are pleased with the 2013 year to date results showing a 12.9% increase of
revenues compared to the first half of 2012 and a net profit of $156,000
compared to a loss of $164,000 for the same period in 2012. We have achieved
these results as we have been focusing our activities on the successful
implementation of our new state of the art manufacturing facility, our top
priority for 2013. Activities in the second quarter progressed as scheduled and
we are on track to complete this major milestone by the end of 2013" said Gilles
Gagnon, President and CEO. "Furthermore, we are very pleased with the
significant progresses made for the financing of this $5.0 million project in a
non-dilutive manner. We thank our partners who believe in and greatly support
Ceapro's innovative technologies and products" he added.
The complete financial statements are available for review on SEDAR at
http://sedar.com/Ceapro and on the Company's website at http://www.ceapro.com/.
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business
activities relate to the development and commercialization of active ingredients
for personal care and cosmetic industries using proprietary technology and
natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.
CEAPRO INC.
Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
Unaudited
Quarters Ended June 30, Six Months Ended June 30,
2013 2012 2013 2012
$ $ $ $
----------------------------------------------------------------------------
Revenue 1,012,322 1,490,131 3,024,601 2,679,644
Cost of goods sold 433,204 817,217 1,395,589 1,337,911
----------------------------------------------------------------------------
Gross margin 579,118 672,914 1,629,012 1,341,733
Research and product
development 226,738 267,142 364,449 429,614
General and
administration 436,473 489,605 872,986 881,493
Sales and marketing 46,570 55,008 68,923 126,434
Finance costs (note 12) 24,137 27,926 74,643 54,662
----------------------------------------------------------------------------
Income (loss) from
operations (154,800) (166,767) 248,011 (150,470)
Other operating income
(loss) (note 11) (96,915) 6,221 (91,555) (13,592)
----------------------------------------------------------------------------
Net income (loss) for
the period (251,715) (160,546) 156,456 (164,062)
Other comprehensive loss
Actuarial loss on
employee future benefit
obligation (note 7) - - (16,916) -
----------------------------------------------------------------------------
Total comprehensive
income (loss) for the
period (251,715) (160,546) 139,540 (164,062)
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Net income (loss) per
common share (note 18):
----------------------------------------------------------------------------
Basic (0.00) (0.00) 0.00 (0.00)
----------------------------------------------------------------------------
Diluted (0.00) (0.00) 0.00 (0.00)
----------------------------------------------------------------------------
Weighted average number
of common shares
outstanding 60,278,948 60,278,948 60,278,948 60,278,948
----------------------------------------------------------------------------
----------------------------------------------------------------------------
FOR FURTHER INFORMATION PLEASE CONTACT:
Branko Jankovic
Vice President and CFO
Ceapro Inc.
(Edmonton): 780.917.8376
bjankovic@ceapro.com
Ceapro (TSXV:CZO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Ceapro (TSXV:CZO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
